Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) - Episode 6

RATIONALE-306 Data on Tislelizumab in ESCC

,

Dr Yoon introduces tislelizumab, an anti-PD-1 immunotherapy regimen being investigated as a first-line ESCC treatment option in combination with chemotherapy, and discusses recent conference data from the RATIONALE-306 trial.

EP. 1: Trends in ESCC Incidence and Observations from Clinical Practice
EP. 2: Approaches to Biomarker Testing for ESCC
EP. 3: The Impact of Biomarker Results on Prognosis and Treatment Decision-Making
EP. 4: First-Line Options for Advanced/Metastatic Disease
EP. 5: Insights on ESCC First-Line Treatment Selection
Now Viewing
EP. 6: RATIONALE-306 Data on Tislelizumab in ESCC
EP. 7: The Potential Impact of Tislelizumab on First-Line ESCC Treatment
EP. 8: Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers
EP. 9: A Look Towards the Future of ESCC